TG Therapeutics | TGTX - Interest Expense On Debt


TG Therapeutics reported $16.57M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Amgen USD 95.64B 94.98B Jun/2026
Ardelyx USD 5.6M 160K Mar/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Curis USD 178K 441K Dec/2023
Gilead Sciences USD 247M 7M Jun/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Novartis USD 462M 119M Jun/2026
Novavax USD 5.82M 342K Dec/2025
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
TG Therapeutics USD 16.57M 8.91M Jun/2026
Verastem USD 382K 33K Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025